Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03414112 · ClinicalTrials.gov registry record · Early Phase 1
The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa
A Early Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT03414112 is a Early Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 16 participants.
The verdict
NCT03414112, a Early Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will use a randomized, controlled, double-blind design involving the administration of intranasal oxytocin (INOT) or placebo to adults with anorexia nervosa, restricting subtype and age-matched controls prior to neuroimaging to assess the impact on frontolimbic brain activity in response to socioemotional stimuli as well as eating behavior in a test meal paradigm.
Interventions
- BIOLOGICAL Intranasal oxytocin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-09-25 |
| Est. Completion | 2021-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03414112
The ClinicalTrials.gov registry entry for NCT03414112 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intranasal oxytocin is the first listed.
NCT03414112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03414112 about?
NCT03414112 is a clinical study titled "The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa". This study will use a randomized, controlled, double-blind design involving the administration of intranasal oxytocin (INOT) or placebo to adults with anorexia nervosa, restricting subtype and age-matched controls prior to neuroimaging to assess the impact on frontolimbic brain activity in response ...
What is the current status of trial NCT03414112?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2018-09-25. Estimated completion is 2021-04-30.
What interventions are being tested in trial NCT03414112?
The interventions under investigation include: Intranasal oxytocin (BIOLOGICAL).
Who is sponsoring clinical trial NCT03414112?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.